A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.
“There was no evidence of improvement in time to recovery in participants who took this dose of fluvoxamine versus those who took a placebo,” said Adrian Hernandez, M.D., the study’s administrative principal investigator and executive director of the DCRI.
Findings appear on medRxiv, a pre-publication server, and have been submitted to a peer-reviewed journal.
Researchers looked at the rate of sustained recovery, defined as three days without symptoms, in ACTIV-6. While 75% of participants were still reporting symptoms on day 7, the majority (82%) of these participants reported no limitation in activities.